Entities

Robin Capital is the Berlin-based European early-stage venture capital manager Robin Capital GmbH, registered in Berlin-Charlottenburg under HRB246428 and published as a registered alternative investment fund manager. Founder and Managing Partner Robin Eric Haak leads a founder-to-founder investment approach, backing enterprise technology across AI, software infrastructure, climate, robotics, space and other deep technology. Its official directory publishes three investing team members and seven named limited partners; those LP affiliations are distinct from employment. Robin Fund One reached a EUR13 million final close, with an additional EUR2 million growth-focused vehicle reported separately. Robin Fund II GmbH & Co. KG reached a EUR12 million second close in 2026; its EUR15 million objective is a target, not a verified final close. The manager is distinct from Robinhood and similarly named investors. Historical founder angel investments are not automatically investments by this manager.

S3 Ventures is an Austin-based venture-capital firm founded in 2005 by Brian R. Smith, investing in seed, Series A and Series B business-technology and health-care-technology companies nationwide. Its portfolio spans enterprise AI, automation, AI computing and quantum technology as well as medical devices and neurological assessment, including BrainCheck and stroke-intervention developer RapidPulse. The firm is backed by a single philanthropic family limited partner and emphasizes patient capital and operational support. Its announced $1 billion-plus assets under management and aggregate portfolio-company fundraising are distinct from individual fund closes. S3 announced a $250 million seventh fund in 2022 and a $250 million eighth fund in December 2025; these public fund announcements do not establish that every commitment had been paid or an exact legal closing day. The current public directory identifies eleven staff. Charlie Plauche is labeled Managing Director in that directory and General Partner in his individual biography, a source discrepancy retained explicitly. The unrelated s3venture.com advertising business is excluded.

Wavemaker Partners is a Singapore-based venture capital group investing in and building enterprise, deep-tech and sustainability businesses across Southeast Asia. Its Ventures strategy backs early-stage companies, while Wavemaker Growth provides follow-on capital and operational support for companies scaling around Series B and beyond. The group combines investment teams with portfolio management, talent, finance, legal and communications support to help founders commercialize technology and expand regionally. The separately branded Wavemaker Impact platform co-founds climate-technology startups.

Amgen Ventures is Amgen’s corporate venture-capital function, established November11,2004 to support emerging biotechnology companies and human therapeutics. Its legal investment entity Amgen Ventures LLC is expressly identified in issuer SEC disclosures as a wholly owned subsidiary of Amgen Inc.; Amgen’s own2025 participating-company list independently names that LLC at OneAmgenCenterDrive,ThousandOaks. The retained institutional buyer profile represents the branded venture function and documented LLC, rather than automatically attributing every venture investment directly to the parent. Amgen Ventures invests in therapeutics, drug discovery, new biological modalities, healthcare technology and digital analytics, including neuroscience, neurodegeneration and AI-enabled discovery. Its current own business-development directory identifies Gladys Nunez as Executive Director,Ventures and Joshua Crapser and Jacob Tutor as Managers within Amgen Ventures. Rachna Khosla’s SeniorVicePresident,BusinessDevelopment role expressly oversees the venture function and is qualified as corporate oversight. Historical Janis Naeve and Samantha Palmer leadership references are not substituted for the live current roster. The current website reports over1B in equity investment and over70 investments: cumulative deployment, not a newly closed LP fund. The original2004 initial100M corporate commitment and a later brochure’s625M sponsor commitment/over400M deployment likewise describe corporate investment capacity/history, not verified outside-LP closes. GoldenTicket laboratory support, commercial partnerships and equity investment are distinguished. Exact current separate LP fund vehicles or actual LP closings are not established by reviewed primary evidence. All preexisting portfolio records, roles and personal attributions are preserved.

Berlin-based venture capital firm operated by Discovery Ventures Management GmbH. General partners Jan Deepen and Stefan Jeschonnek previously co-founded SumUp and Zeitgold; Jasper Masemann brings experience at Cherry Ventures and HV Capital. The firm backs early-stage technology businesses, emphasizing fintech, B2B SaaS and artificial intelligence, and describes its venture strategy as a microfund with typical initial pre-seed and seed checks of EUR200,000–1 million and follow-on investment. Its separate Specialty Capital strategy offers deal-by-deal private-market investments. Verified historical backing includes AI developer platform CopilotKit, fund-infrastructure company NaroIQ, autonomous robotics company ARX Robotics, education platform Knowunity, cultivated-meat company Gourmey (now Parima), crypto infrastructure company Unstoppable Finance, and cyber-insurance company Baobab. Its current published directory names eight team members, including Pia Leonhard on maternity leave. No closed fund amount is asserted from the check-size range or registered vehicles.

Investment organization supporting the Hillman family and Hillman Family Foundations, investing globally in private equity funds and co-investments.

Research university. University identity is distinct from any separately managed venture fund or investment arm.

WI Harper Group is a cross-border venture capital platform founded in1993, investing in early and growth-stage technology and life-sciences companies in the United States and Greater China. Its strategy combines sector expertise, operational support, financing, partnerships and international market access, with interests in AI, biotechnology, healthcare, semiconductors, enterprise technology and sustainability. The current website publishes17 operating team members across San Francisco, Beijing and Taipei. Chairman and founder Peter Liu is also identified in legal filings as Pete Yeau-Hwan Liu. Current directory titles are used when older individual biographies differ, including Edward Liu, Kelvin Sun, Eric Fu, Emily Guo and Alexander Cheng. The retained WI Harper Group brand record and Investor4913 preserve their existing Appier and nWay investments. Legal management and subscribing vehicles are separate: April15,2025 SEC ERA Final filing names WI Harper INC VI Management Limited, CRD161666, and lists wiharper.com; it establishes that entity’s historical advisory identity rather than asserting ongoing SEC registration for the whole platform. SEC shareholding filings disclose Fund VIII LP through its Management LP and WI Harper Fund VII GP LLC, whose sole member is Peter Liu. The current group website remains active and its corporate/legal fund affiliations are source-qualified. Primary manager releases prove Fund VII closed atUSD110M onJune30,2011, Fund VIII announced its oversubscribedUSD175M closing onMay17,2016, and the jointly managed Innovation Works Development Fund closed atUSD180M as announcedSeptember1,2011. The November2020 Fund IX FormD offeredUSD150M but reported zero sold and no first sale, so its target is not recorded as a completed close. Alibaba’s own timeline confirms a separate delegated Taiwan investment mandate; allocated commitments are not assumed newly raised paid cash. Current homepage and about-page counts differ between eight and nine funds and between250-plus and400-plus companies; these self-reported aggregates andUSD1B-plus AUM/committed capital are not individual closes. Current own published portfolio metadata has100 company records. Lab, board and personal family-office relationships are not automatically platform cash checks; buyer sources and subscribing vehicles remain qualified.

CDP Venture Capital SGR S.p.A. is an Italian venture-capital investment manager supporting innovative startups, SMEs and research commercialization through direct funds, funds of funds, acceleration, technology transfer and corporate venture building. Its current legal disclosure identifies Rome registration and tax/VAT number 08480100018 and AIF-manager register number59. CDP Equity owns70% and Invitalia30%; these shareholders are distinct legal organizations. The manager operates in Rome and Milan. Its public strategies cover artificial intelligence, deep technology, biotechnology, medical technology, space, quantum computing and other sectors of national interest. The Evolution (Evoluzione) Fund invests in validated or technologically advanced deeptech ventures, typically SeriesA–B, and has EUR150million in actual subscribed capital reported at year-end2025. The Artificial Intelligence fund likewise has separate subscribed capital; public allocations, targets and manager-wide assets are distinguished from company investment proceeds and cash drawn. The2025 annual report identifies EUR4.871billion of investor-subscribed capital across its managed vehicles; this is not one fund or a new company round. Current native management and fund pages supply98 unique named team members with authentic published portraits. Some older governance and brochure listings have dated terms or superseded personnel and are not automatically current. This preserved Goldi-origin record (Investor4725) uses the same public manager name as the canonical full directory CDPVentureCapitalSGR (Investor2045). Its existing historical investment rows and protected references remain attached here; the current full team and fund directory are maintained under2045 to avoid duplicate staffing, funds or new buyer checks. Historical legal-name continuity: the manager’s own January21,2020 announcement states that Invitalia Ventures SGR was renamed CDP Venture Capital SGR S.p.A. by its shareholders. Invitalia, the national development agency, is a separate shareholder and is not substituted as the historical operating fund manager. Invitalia’s December29,2016 announcement names Empatica among completed October–December investments by Italia Venture I, managed by Invitalia Ventures SGR. This supports the same legal manager’s historical backing, without independently establishing the issuer’s exact closing day, aggregate round amount, individual ticket or lead status. Canonical full directory Investor2045 is used for one source-qualified new check; protected legacy4725 references remain preserved without alias merging.

Cercano Management is an investment adviser serving high-net-worth individuals, families and related organisations. It builds customized portfolios across public markets and private investments, including venture capital, private equity and private credit, and combines investment management with tax and estate planning, family governance, philanthropy and operational support. Its venture team backs technology businesses; for example, it participated in Doorstep’s September2025 seed financing for AI and phone-sensor technology that verifies last-mile deliveries inside buildings. The firm’s current venture-capital platform is co-led by YB Choi and Stuart Nagae. Founded in2021 by investment professionals with family-office experience, Cercano draws on prior direct-investing work at Vulcan Capital, while operating under its own identity. The firm’s strategies and assets under management are distinct from the corpus of an individual new venture fund.

Greencode Ventures is a Helsinki-headquartered venture capital firm backing European startups that apply AI and digital technology to energy, industry and infrastructure. It invests from seed through Series A, with published tickets up to EUR5 million. The firm began investing in 2023 and was founded by Kaisa Hietala, Terhi Vapola and Ines Bergmann-Nolting. Its portfolio includes Ubotica, Ora Computing, LiveEO, Groundhawk and Supercritical. Its current public directory lists nine team members and three advisers. The August 2023 first-close announcement reported nearly EUR40 million, and its 2024 impact report described approximately EUR55 million raised at the latest close, explicitly stating that this was not the final close.

Lasagna is the US venture capital platform at makelasagna.co, investing behind founders who have already built and exited multiple companies, as early as the pre-idea stage. It works alongside those founders on their next ventures. Grant Gittlin publicly launched his first dedicated Lasagna fund in February2023; the company page self-reports founding2021, which is distinct from the legal fund formation and first investment-sale dates. AI-related primary financing evidence includes Fourier Health’s prior pre-seed, enterprise AI-impact intelligence company Parable and Circuitry.ai’s decision-intelligence/service-AI platform. Individual check sizes and subscribing-fund allocations are undisclosed. The Fourier USD8.4M seed announcement separately names Lasagna among prior pre-seed investors; it does not establish participation in that later priced seed round. The pre-seed relationship is handled by the sole Fourier issuer owner. Exact legal management, reviewed October8,2026: SEC filings for Delaware venture funds Lasagna1LP (CIK2034362, formed2023) and Lasagna2LP (CIK2095814, formed2025) identify LasagnaCapitalLLC as investment manager. Their distinct GPs are Lasagna1GPLLC and Lasagna2GPLLC, with GrantGittlin principal of the GP. Retained GoldiLasagna/Investor4770 represents this branded investment manager, not a new duplicate legal fund. The SEC-disclosed principal office is Miami Beach, Florida. Platform-service advisers and administrators are not assumed to be the investment manager, and a purported external adviser-registration association remains unasserted. Lasagna design studio in Squamish/Canada at lasagna.studio is a separate business; NateSmith and DaveMalarenko from that studio are excluded from this investment firm. Public-team scope: founder/investor GrantGittlin and publicly listed affiliates AndrewRoth, LindyWhittlesey, KellyFreedman and AmandaFloresDunn are included with role certainty explicitly qualified. Lindy’s own profile describes investing in multi-exit founders and names Lasagna; Kelly’s own profile names Lasagna. Exact executive ranks and appointment dates are not proven by current primary sources, so secondary partner/COO/chief-of-staff titles are not asserted. Amanda’s individual profile now lists BME Strategies & Events while the company page still lists her; her Lasagna affiliation is qualified rather than presumed current employment. Andrew’s authentic individually named portrait comes from the own company listing. Grant’s authentic named first-hand interview photograph is historical2016, not presented as a newly taken2026 portrait. Authentic individually attributable portraits for Lindy/Kelly/Amanda remain gaps; anonymous LinkedIn member photos are not assigned by their page order. The public list is not a claim that all privately employed staff are known. Two distinct actual fund offerings are verified directly from SEC filings and submission histories. FundI first sold June6,2023; its August27,2024 filing reports USD39,087,500 sold to85 investors against a USD50M offering, with USD10,912,500 remaining. FundII first sold April17,2026; its April22,2026 filing reports USD34,040,000 sold to54 investors, including a GP commitment, against a USD50M offering, with USD15,960,000 remaining. Fund amounts record these disclosed sold commitments as of each filing, not final closes or paid-in cash, and both50M targets are excluded from closed-capital totals. No AUM, portfolio valuation or target is booked as additional cash. A distinct Lasagna Blockskye Series C SPV2025 appears in the SEC adviser disclosure under LasagnaCapitalLLC/Sydecar; exact current paid/sold capital is not established and is not added as a third cash fund. Existing Blockskye participation46559 and its round15159 are preserved; its imported stage needs a separate issuer-level source audit, not a manager-side cash migration. Parable/Circuitry.ai are queued for full issuer enrichment before new checks, rather than creating bare company records.

Provides a card-issuing platform that enables businesses to create payment cards, authorize transactions and manage card programs through APIs.

Mission BioCapital is a venture capital firm that invests in and helps build early-stage life science companies, with a focus on novel therapeutics and selected medical technology and diagnostics opportunities. It combines capital with scientific expertise, company-creation support and access to shared laboratories through MBC BioLabs, LabCentral and BioLabs. Its Platinum Program provides selected founders with pre-seed capital, laboratory space and development services.

Integrated financial-services group with insurance, health and senior-care businesses. The group identity is distinct from any named venture-capital subsidiary or fund.

Privately held investment and operating company founded by Michael Eisner, investing in, acquiring and operating media and entertainment businesses.

Vitruvian Partners is an international growth-capital and buyout investor backing businesses undergoing rapid growth or major market change. It makes minority and majority investments, supplies primary and secondary growth capital, and undertakes public-to-private transactions. Its strategy spans technology, data and business services, consumer internet and healthcare, including AI-enabled software and deep technology. An operating team supports portfolio companies with international expansion, technology, sales, finance, people and acquisitions. The group operates through Vitruvian Partners LLP and affiliated entities; the LLP is the authorised manager of its Vitruvian Investment Partnership funds.

Z Venture Capital (ZVC) is the wholly owned corporate venture capital subsidiary of LY Corporation. It invests from seed through growth stages in Japan, South Korea, the United States and Southeast Asia, connecting founders with the group’s commercial resources and regional networks. Its focus spans media, commerce, fintech and artificial intelligence, with expanding investments in physical AI, space technology and robotics. Teams operate from Tokyo, Seoul and San Francisco and support portfolio companies through follow-on investment, business partnerships and value creation. The legal company was established in August 2012 as YJ Capital; the ZVC platform emerged from its April 2021 merger with LINE Ventures. It is distinct from XYZ Venture Capital.

Daiichi Life Insurance Co., Ltd. is the Japanese operating life insurer formerly styled The Dai-ichi Life Insurance Company, Limited. Its current own English profile uses the new name as of1April2026 and identifies president Toshiaki Sumino and its Tokyo headquarters. The corporate brand traces its1902 mutual-insurance origins, but the parent’s official leadership biographies explicitly distinguish the operating insurer before and after the1October2016 holding-company restructuring as different legal companies. The current holding parent is separately Daiichi Life Group, Inc., formerly Dai-ichi Life Holdings, Inc.; it is not automatically substituted as a2019 startup subscriber. The insurer conducts life-insurance business and corporate/impact investment from its insurance investment portfolio. Its July5,2019 primary release explicitly says the operating insurer impact-invested in Neurotrack, the cognitive/eye-tracking technology company, and reports USD7M invested (approximatelyJPY800M). The same release’s JPY1.6B headline spans CureApp and Neurotrack and is not assigned whole to either company; CureApp’s cumulative funding wording also prevents treating every headline as new cash. Neurotrack’s own June11,2019 SeriesC names Dai-ichi Life as a new participant. The two primary announcements corroborate the institutional buyer but do not explicitly assign the reported7M to a named tranche, so the retained SeriesC ticket stays undisclosed rather than forced to that amount. The published impact-investment history also names AI antibody-discovery company MOLCURE, robot/avatar developer MELTIN MMI, biomaterials company Spiber, digital-therapeutics companies CureApp and SUSMED, low-vision laser technology QD Laser and wind-energy technology Challenergy. Those are specific issuer/insurer primary relationships; dates of company cash closings, named subscribing accounts and individual amounts require separate proof. Its April2019 Alternative Investment Department is a corporate investment function, not a separately invented venture fund or manager. Total assets, capital, programme budgets and insurance liabilities are not LP fund closes. The insurer’s1October2026 roster publishes10 directors, five statutory auditors and29 executive officers including three director/executive overlaps:41 distinct named people. Their roles and functional mandates are sourced from the exact insurer roster and same-day responsibilities document. Genuine parent-published portraits are used only where English biographies independently confirm the same insurer officials; absent portraits remain explicit source gaps. Existing raw investor4581 and legacy3550 identities, cash links and protected provenance are retained. The3550 record’s inherited InvestmentFirm type is qualified as a legacy insurer attribution, not an invented private VC or holding-company identity.

DeepWork Capital is an Orlando-based early-stage venture capital firm investing in technology and life sciences, primarily in U.S. regions historically underserved by venture capital, including Florida and surrounding markets. The firm traces its history to 2015; the DeepWork Capital LLC adviser entity was established in January 2018. It targets seed and Series A companies and provides hands-on help with strategy, financing and operations. Co-founders and Managing Partners Mitchel Laskey, Ben Patz and Kathy Chiu lead a ten-person public team. Its portfolio includes industrial and enterprise AI, robotics, space technology and neurological drug-development companies, including Circuitry.AI, Caspia Technologies, Tompkins Robotics, X-Lumin, Astrocyte Pharmaceuticals and Myosin Therapeutics. Its March 2026 SEC adviser filing lists eight distinct fund vehicles. These include the FAN funds, DeepWork Fund III, a parallel fund and an Astrocyte vehicle; it also serves as investment adviser to the separately governed Florida Opportunity Fund. DeepWork Capital is investment sub-adviser to CNL Strategic Venture Capital, a distinct business development company. It participated in Rapta's $8 million financing announced September 2026. Individual fund asset values and offering targets do not establish fundraising totals.

European Union lending institution and multilateral public financial institution. Loans, venture debt, equity co-investments and investment-fund activity must retain their actual financing type; EIB is distinct from the European Investment Fund and is not a conventional venture capital firm.

HealthQuad is a specialist healthcare venture and early-growth investment platform focused on India and Asia, operating as Quadria Capital’s early-growth arm. It backs commercially established companies in digital health, medical devices and diagnostics, new models of healthcare delivery, and technology across biotechnology and pharmaceuticals. Its strategy addresses healthcare access, affordability and quality through scalable technology, product and business-model innovation, including AI-assisted diagnostics, mental-health support, remote patient monitoring and clinical data systems. The team combines investment work with clinical and operating expertise, thematic research, hands-on company development, regulatory and commercial support, and access to Quadria’s healthcare network. Its current and predecessor funds have backed companies including Wysa, Qure.ai, Cureskin, THB and LifeSigns. Fund III announced INR550 crore of first-close commitments in June 2026; larger published fundraising targets and platform AUM are separate from committed fund capital. Predecessor funds and their published personnel retain distinct historical and vehicle affiliations following the sponsors’ 2025 separation; HealthKois is not an alias of HealthQuad.

Leo Capital is an early-stage venture investment firm headquartered in Singapore and Helsinki, with a team spanning Asia, Europe and the United States. Founded by entrepreneurs, it leads or co-leads pre-seed and seed investments and supports companies through subsequent fundraising and international expansion. Its interests include applied and generative AI, enterprise software, fintech, health technology, life sciences and deep technology. Beyond capital it helps founders reach enterprise customers, hire senior talent and build cross-border financing networks. Its European activity includes a dedicated Nordic fund backing technology startups.

Mitsui & Co. Global Investment, Inc. (MGI) is the venture-investment subsidiary of Mitsui & Co., Ltd., investing in technology and life-sciences companies through its own investment partnerships. Established in 2001 as Mitsui & Co. Venture Partners, Inc., it adopted its current name in 2010. Its public offices include Menlo Park and Tokyo. MGI combines venture investing with the parent’s international industrial network; its portfolio includes healthcare AI, computational biology, ALS and neuropsychiatric drug development, neurological care, quantum-dot devices and industrial technologies. The current public team has 13 named investment, finance, administrative and advisory people. Some published functions explicitly relate to the separate E12 Ventures joint platform. E12 Fund I’s USD105M final commitments are not attributed as a directly managed MGI fund: its general partner is a separately constituted joint venture. Primary SEC filings identify legacy MCVP investment vehicles, whose fund sizes and close dates are undisclosed in the reviewed evidence. The parent company remains a separate investor identity.

Swiss nonprofit foundation supporting the decentralized NEAR ecosystem. Grants and ecosystem investments should be distinguished from a standalone venture capital firm.

Pioneer Square Labs (PSL) is a Seattle startup studio and broader company-building brand founded in2015. Its studio works with founders to validate ideas and create technology businesses, including AI applications, and provides engineering, design, operations and investor support. The current public directory publishes14 operating/investment people and an eight-member Technical Advisory Board. PSL Studio and the associated PSL Ventures investment unit are separate entities with separate operations and overlapping leadership/support teams. PSL Ventures backs external pre-seed, seed and SeriesA companies and participates in studio spinouts, while studio membership or a company-creation programme alone does not establish a priced fund investment. The existing PSL investor identity and its three legacy company links are preserved; new unit-specific financing is attributed to the separately identified PSL Ventures manager. The studio reported USD20M of company-creation capital in2023 and described earlier studio raises in rounded terms; those operating-capital raises are not a fictitious VenturesFundIII or manager-wide AUM.

Seed-stage venture capital firm backing immigrant founders and deep technical innovation. Its portfolio spans AI software, inference semiconductors, robotics, synthetic biology and brain-health technology, with KeyWise AI among its investments.

German healthcare venture investor that backs digital health, medical technology and healthcare service businesses at early stage and during growth. Its team combines healthcare operations and investment experience, supporting portfolio management teams with industry advice and networks. Its investments include neurosurgical microrobotics company Robeauté, diagnostics businesses and digital care providers. Its website currently says it is not investing in new projects.